Biliary tumor or cancer is a type of cancer that progresses in the bile duct system. The system connects the liver, gallbladder, and small intestine, and helps in moving bile, which is a fluid that helps to digest fats. It is expected that approximately 15,000 people in the United States are diagnosed with biliary cancer each year. One of the major risk factors for this type of cancer is the rising geriatric population across the world; with increasing age, the risk of all bile duct cancers increases. As an example, according to the United Nations Department of Economic and Social Affairs, in 2017, 962 million people were aged 60 and above, and it was estimated that 62% of the people in the aforementioned age group live in developing countries. This number is expected rise rapidly in the coming years.
Few more risk factors for developing all types of biliary cancers are smoking and obesity. Women who have a history of gall stones are more likely to be diagnosed with gall bladder cancer and the other Infections, mainly hepatitis viruses that affect the liver is also a risk factor. There are some experimental medications currently being tested for the treatment of biliary and gall bladder cancers.
This report by Mordor Intelligence provides extensive insights on the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials across major regions of the world, are provided, with data obtained from multiple sources. The report also comprises of a list of key sponsors, having pipeline products for the concerned market.
The report will cover the analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stake holders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary and primary research are validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports are continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation- by Phase
6.1 Phase III Product Candidates
6.2 Phase II Product Candidates
6.3 Phase I Product Candidates
7. Clinical Trials Segmentation- by Status
7.6 Other Statuses
8. Pipeline Therapeutic Assessment (Info graphic Charts and Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence